Membrane-associated matrix proteolysis and heart failure.
about
Antifibrotic therapies to control cardiac fibrosisTargeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitorsCardiac matrix: a clue for future therapyPlasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction StudyCurrent Understanding of the Pathophysiology of Myocardial Fibrosis and Its Quantitative Assessment in Heart Failure.Substance P acting via the neurokinin-1 receptor regulates adverse myocardial remodeling in a rat model of hypertension.Transcriptional changes in bone marrow stromal cells of patients with heart failure.Sphingosine 1-Phosphate Receptors: Do They Have a Therapeutic Potential in Cardiac Fibrosis?Inhibition of MMP-2 expression with siRNA increases baseline cardiomyocyte contractility and protects against simulated ischemic reperfusion injuryPreclinical evaluation of the engineered stem cell chemokine stromal cell-derived factor 1α analog in a translational ovine myocardial infarction model.Targeted injection of a biocomposite material alters macrophage and fibroblast phenotype and function following myocardial infarction: relation to left ventricular remodelingTranscriptional profiling of left ventricle and peripheral blood mononuclear cells in a rat model of postinfarction heart failure.Sizing up models of heart failure: Proteomics from flies to humans.Ezh2-mediated repression of a transcriptional pathway upstream of Mmp9 maintains integrity of the developing vasculature.Pentosan polysulfate decreases myocardial expression of the extracellular matrix enzyme ADAMTS4 and improves cardiac function in vivo in rats subjected to pressure overload by aortic banding.Prostacyclin analogue beraprost inhibits cardiac fibroblast proliferation depending on prostacyclin receptor activation through a TGF β-Smad signal pathway.Local hydrogel release of recombinant TIMP-3 attenuates adverse left ventricular remodeling after experimental myocardial infarction.Overexpression of TFAM or twinkle increases mtDNA copy number and facilitates cardioprotection associated with limited mitochondrial oxidative stressTemporal and Molecular Analyses of Cardiac Extracellular Matrix Remodeling following Pressure Overload in Adiponectin Deficient MiceNon-human primate and rat cardiac fibroblasts show similar extracellular matrix-related and cellular adhesion gene responses to substance P.Matrix Metalloproteinase-2 Polymorphisms in Chronic Heart Failure: Relationship with Susceptibility and Long-Term Survival.Low MMP-8/TIMP-1 reflects left ventricle impairment in takotsubo cardiomyopathy and high TIMP-1 may help to differentiate it from acute coronary syndromeImmunosuppression With FTY720 Reverses Cardiac Dysfunction in Hypomorphic ApoE Mice Deficient in SR-BI Expression That Survive Myocardial Infarction Caused by Coronary Atherosclerosis.Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.Biotic acts of antibioticsLocalized targeting of biomaterials following myocardial infarction: a foundation to build onp90 ribosomal S6 kinase 3 contributes to cardiac insufficiency in α-tropomyosin Glu180Gly transgenic miceMatrix metalloproteinases 2 and 9 are differentially expressed in patients with indeterminate and cardiac clinical forms of Chagas diseaseIntegrating the myocardial matrix into heart failure recognition and management.Secreted Frizzled-related protein 2 as a target in antifibrotic therapeutic intervention.Mechanistic relationship between membrane type-1 matrix metalloproteinase and the myocardial response to pressure overload.Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction.The therapeutic potential of miRNAs in cardiac fibrosis: where do we stand?Matrix metalloproteinases are involved in cardiovascular diseases.Docosahexaenoic acid reverses angiotensin II-induced RECK suppression and cardiac fibroblast migration.Cardiac Physiology of Aging: Extracellular Considerations.Recent Developments in Heart Failure.Cardiac Remodeling: Concepts, Clinical Impact, Pathophysiological Mechanisms and Pharmacologic Treatment.Extracellular Ubiquitin: Role in Myocyte Apoptosis and Myocardial Remodeling.Matrix Metalloproteinases in Myocardial Infarction and Heart Failure.
P2860
Q26745841-34E08A4F-7D77-4761-86C5-4302EF00822AQ26830555-0A2246BC-26C6-4D87-93ED-3A9E2C31C164Q27026864-EE892ADC-5A12-47E0-8FAE-B96E6D47E34EQ31036336-5950A1CB-359A-4EC8-A812-D7B181CCB96BQ33595504-F6BC46B7-B5C9-4A1F-A0DD-DE0CACF54B24Q33705797-BA11A74D-0DFA-413C-9A81-A44AFB70AD77Q33728924-B395D76C-A218-4E6A-8431-454A6AD0ACCAQ33753317-ACF204F5-36AF-4C2D-8DDA-F3EF1B055D7EQ34039481-C1C92968-C015-4DAC-BACE-80C40139AA62Q34065859-4E369365-488A-4DB5-BFD5-FEF10514708EQ34125089-036CD049-6E32-45A4-80C6-5BAA41EE1E79Q34481362-C0F66D0C-AD80-4217-A610-D369BF1BBEFDQ34808730-9D811AA1-1065-4247-A2F1-FEEA3585F0E6Q34999341-BEAAC254-915A-4BE4-A16A-43CBEDA0C87AQ35111270-38AA6673-24EA-4C24-8779-A76B146BFC31Q35172597-8EB02DBE-2DA9-478F-912C-F5C059563A18Q35194787-BA7616AC-4A82-4532-A3DA-CD1A3C5FF2FBQ35231383-473226AF-1872-409F-83CD-BBE8FD53E0CCQ35614083-7A42EA97-C6E7-4BEE-ADCE-50EEAD643DCEQ35821484-42DA725F-953D-4872-963B-EA53F62AA486Q36110240-C2866601-8E2C-4A29-8E10-824AC484A4B0Q36302470-11CF8FAC-9CE8-4D0A-BC3E-1B1BC794AD5AQ36437116-A2AE18F7-6E3F-413F-8375-4C952EAB726DQ37058596-EB8629FD-0455-400A-A30A-08E93DE25126Q37101851-1EAD0E11-84D0-40F0-90C1-CBB1FDA44515Q37170581-1253F43F-C9F3-4184-A842-7EA4ED665C25Q37234815-16E2A4D2-9588-4BCE-9DF5-35854A1B1CE5Q37264609-335B8B30-8BBA-4B47-9B01-4D2F371BA2EBQ37406111-CDA7FD8E-3BA1-41C7-A57B-53606557CEDDQ37629036-8E9B68BA-0A19-472B-B50D-642E35C69D8EQ37652827-4D2707DB-4F6C-4B2E-9928-0727F7196D66Q38110226-4C109A81-029D-43E0-A569-55B6F48343CDQ38118947-B850EF4B-40C7-4F27-B2C7-D6360BFE9BB5Q38224193-9D732143-0D0D-4BD6-854F-D5A8B79067CCQ38261562-102FFAA6-1178-4F0E-955F-C2A452DA0B1EQ38542448-E81E7912-B79B-4142-8B92-CF382398F0ACQ38584364-749ECAA5-8CC4-4E1D-B511-BA912811850CQ38662968-76BBB96E-5395-4F82-8160-EAEA8DE0C538Q38693302-FD741B35-DEBC-457F-9682-42FDB33E1D32Q38729906-AF5257F6-7374-4811-A136-E2F468798ED5
P2860
Membrane-associated matrix proteolysis and heart failure.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Membrane-associated matrix proteolysis and heart failure.
@ast
Membrane-associated matrix proteolysis and heart failure.
@en
type
label
Membrane-associated matrix proteolysis and heart failure.
@ast
Membrane-associated matrix proteolysis and heart failure.
@en
prefLabel
Membrane-associated matrix proteolysis and heart failure.
@ast
Membrane-associated matrix proteolysis and heart failure.
@en
P2860
P1433
P1476
Membrane-associated matrix proteolysis and heart failure
@en
P2093
Francis G Spinale
Joseph S Janicki
P2860
P304
P356
10.1161/CIRCRESAHA.112.266882
P577
2013-01-01T00:00:00Z